Imbria Pharmaceuticals' ninerafaxstat demonstrated statistically significant improvements in cardiac energetics, left ventricular reserve capacity, and exercise performance in patients with cardiometabolic HFpEF in the Phase 2 IMPROVE-DiCE trial.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.